Cargando…

Effectiveness of option B highly active antiretroviral therapy (HAART) prevention of mother-to-child transmission (PMTCT) in pregnant HIV women

BACKGROUND: Ensuring that no baby is born with HIV is an essential step towards achieving an AIDS-free generation. To achieve this, strategies that decouple links between childbirth and HIV transmission are necessary. Traditional forms of prevention of mother-to-child transmission of HIV (PMTCT), ha...

Descripción completa

Detalles Bibliográficos
Autores principales: Ngemu, Erastus K, Khayeka-Wandabwa, Christopher, Kweka, Eliningaya J, Choge, Joseph K, Anino, Edward, Oyoo-Okoth, Elijah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3898637/
https://www.ncbi.nlm.nih.gov/pubmed/24447387
http://dx.doi.org/10.1186/1756-0500-7-52
_version_ 1782300450387656704
author Ngemu, Erastus K
Khayeka-Wandabwa, Christopher
Kweka, Eliningaya J
Choge, Joseph K
Anino, Edward
Oyoo-Okoth, Elijah
author_facet Ngemu, Erastus K
Khayeka-Wandabwa, Christopher
Kweka, Eliningaya J
Choge, Joseph K
Anino, Edward
Oyoo-Okoth, Elijah
author_sort Ngemu, Erastus K
collection PubMed
description BACKGROUND: Ensuring that no baby is born with HIV is an essential step towards achieving an AIDS-free generation. To achieve this, strategies that decouple links between childbirth and HIV transmission are necessary. Traditional forms of prevention of mother-to-child transmission of HIV (PMTCT), has been recommended. Recognizing the importance and challenges of combination of methods to achieve rapid PMTCT, the World Health Organization (WHO) recommended option B Highly Active Antiretroviral Therapy (HAART) for all HIV-positive pregnant women. This study aimed to evaluate the effectiveness of the HAART in PMTCT. A cohort of HIV-infected pregnant women in Kenya were obtained from the DREAM Center, Nairobi. The study participants underwent adherence counselling and Option B of HAART [Nevirapine(NVP) + Lamivudine + Zidovudine] at the fourth week of gestation followed by an intravenous NVP administration intrapartum and postpartum NVP syrup to the respective infants for six weeks. Absolute pre-HAART and post-HAART CD4 counts and viral loads counts were determined. Comparison of the CD4 counts and viral loads before and after administration of HAART were done using Wilcoxon’s Matched Pairs Signed-Ranks Test. FINDINGS: The mean absolute CD4 cell counts in mothers after administration of HAART was significantly higher (Z = 15.664, p < 0.001) than before the administration of HAART). Also the viral load of the mothers significantly (Z = 11.324, p < 0.001) reduced following HAART treatment. Following the HAART administration in mothers, up to 90% of children were confirmed to be HIV negative. CONCLUSION: Administration of HAART to mothers and children demonstrated an effective mechanism of PMTCT. However, other aspects of HAART such as adherence, costs, mothers behaviour during HAART, and the child feeding programme during the therapy should further be evaluated and ascertained how they can affect the overall efficacy of option B HAART in PMTCT.
format Online
Article
Text
id pubmed-3898637
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-38986372014-01-23 Effectiveness of option B highly active antiretroviral therapy (HAART) prevention of mother-to-child transmission (PMTCT) in pregnant HIV women Ngemu, Erastus K Khayeka-Wandabwa, Christopher Kweka, Eliningaya J Choge, Joseph K Anino, Edward Oyoo-Okoth, Elijah BMC Res Notes Short Report BACKGROUND: Ensuring that no baby is born with HIV is an essential step towards achieving an AIDS-free generation. To achieve this, strategies that decouple links between childbirth and HIV transmission are necessary. Traditional forms of prevention of mother-to-child transmission of HIV (PMTCT), has been recommended. Recognizing the importance and challenges of combination of methods to achieve rapid PMTCT, the World Health Organization (WHO) recommended option B Highly Active Antiretroviral Therapy (HAART) for all HIV-positive pregnant women. This study aimed to evaluate the effectiveness of the HAART in PMTCT. A cohort of HIV-infected pregnant women in Kenya were obtained from the DREAM Center, Nairobi. The study participants underwent adherence counselling and Option B of HAART [Nevirapine(NVP) + Lamivudine + Zidovudine] at the fourth week of gestation followed by an intravenous NVP administration intrapartum and postpartum NVP syrup to the respective infants for six weeks. Absolute pre-HAART and post-HAART CD4 counts and viral loads counts were determined. Comparison of the CD4 counts and viral loads before and after administration of HAART were done using Wilcoxon’s Matched Pairs Signed-Ranks Test. FINDINGS: The mean absolute CD4 cell counts in mothers after administration of HAART was significantly higher (Z = 15.664, p < 0.001) than before the administration of HAART). Also the viral load of the mothers significantly (Z = 11.324, p < 0.001) reduced following HAART treatment. Following the HAART administration in mothers, up to 90% of children were confirmed to be HIV negative. CONCLUSION: Administration of HAART to mothers and children demonstrated an effective mechanism of PMTCT. However, other aspects of HAART such as adherence, costs, mothers behaviour during HAART, and the child feeding programme during the therapy should further be evaluated and ascertained how they can affect the overall efficacy of option B HAART in PMTCT. BioMed Central 2014-01-21 /pmc/articles/PMC3898637/ /pubmed/24447387 http://dx.doi.org/10.1186/1756-0500-7-52 Text en Copyright © 2014 Ngemu et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Short Report
Ngemu, Erastus K
Khayeka-Wandabwa, Christopher
Kweka, Eliningaya J
Choge, Joseph K
Anino, Edward
Oyoo-Okoth, Elijah
Effectiveness of option B highly active antiretroviral therapy (HAART) prevention of mother-to-child transmission (PMTCT) in pregnant HIV women
title Effectiveness of option B highly active antiretroviral therapy (HAART) prevention of mother-to-child transmission (PMTCT) in pregnant HIV women
title_full Effectiveness of option B highly active antiretroviral therapy (HAART) prevention of mother-to-child transmission (PMTCT) in pregnant HIV women
title_fullStr Effectiveness of option B highly active antiretroviral therapy (HAART) prevention of mother-to-child transmission (PMTCT) in pregnant HIV women
title_full_unstemmed Effectiveness of option B highly active antiretroviral therapy (HAART) prevention of mother-to-child transmission (PMTCT) in pregnant HIV women
title_short Effectiveness of option B highly active antiretroviral therapy (HAART) prevention of mother-to-child transmission (PMTCT) in pregnant HIV women
title_sort effectiveness of option b highly active antiretroviral therapy (haart) prevention of mother-to-child transmission (pmtct) in pregnant hiv women
topic Short Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3898637/
https://www.ncbi.nlm.nih.gov/pubmed/24447387
http://dx.doi.org/10.1186/1756-0500-7-52
work_keys_str_mv AT ngemuerastusk effectivenessofoptionbhighlyactiveantiretroviraltherapyhaartpreventionofmothertochildtransmissionpmtctinpregnanthivwomen
AT khayekawandabwachristopher effectivenessofoptionbhighlyactiveantiretroviraltherapyhaartpreventionofmothertochildtransmissionpmtctinpregnanthivwomen
AT kwekaeliningayaj effectivenessofoptionbhighlyactiveantiretroviraltherapyhaartpreventionofmothertochildtransmissionpmtctinpregnanthivwomen
AT chogejosephk effectivenessofoptionbhighlyactiveantiretroviraltherapyhaartpreventionofmothertochildtransmissionpmtctinpregnanthivwomen
AT aninoedward effectivenessofoptionbhighlyactiveantiretroviraltherapyhaartpreventionofmothertochildtransmissionpmtctinpregnanthivwomen
AT oyoookothelijah effectivenessofoptionbhighlyactiveantiretroviraltherapyhaartpreventionofmothertochildtransmissionpmtctinpregnanthivwomen